Indinavir

Cas No.:	150378-17-9
Chemical Name:	Indinavir
Synonyms:	Indinavir;(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide;H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-Nh2;Indinavir See I525000;(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl);(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}butyl]-N-tertbutyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;L735524;L-735524;MK639;MK-639;N-[2(R)-hydroxy-1(S)-indanyl]-5-{[2(S)-tert-butylaminocarbonyl]-4-(3-pyridylmethyl)piperazino}-4(S)-hydroxy-2(R)-phenylmethylpentanamide;Indinavir&Int.;MK-639：Cfixivan;(1(1S,2R)5(S))-2,3,5-TRIDEOXY-N-(2,3-DIHYDRO-2HYDROXY-1H-INDEN-1-YI)-;[I(1S,2R),5(S)]-2,3,5-Trideoxy-N-(2,3．Dihydro-2-hydrox-Lh-inden-1-y1)-5-[2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-D-erythro-pentonamide
SMILES:	C1N=CC(=CC=1)CN2C[C@H](C(=O)NC(C)(C)C)N(CC2)C[C@@H](O)C[C@@H](CC3=CC=CC=C3)C(=O)N[C@H]4C5C(=CC=CC=5)C[C@H]4O
Formula:	C36H47N5O4
M.Wt:	613.80
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Indinavir(MK-639; L735524) is a potent and specific HIV protease inhibitor that appears to have good oral bioavailability. Indinavir(MK-639) is a protease inhibitor used as a component of highly active antiretroviral therapy (HAART) to treat HIV infection and AIDS.MK-639 appears to have significant dose-related antiviral activity and is well tolerated [1]. Inhibition constants (K(i)) of the antiviral drug indinavir for the reaction catalyzed by the mutant enzymes were about threefold and 50-fold higher for PR(L24I) and PR(I50V), respectively, relative to PR and PR(G73S). The dimer dissociation constant (K(d)) was estimated to be approximately 20 nM for both PR(L24I) and PR(I50V), and below 5 nM for PR(G73S) and PR. Crystal structures of the mutants PR(L24I), PR(I50V) and PR(G73S) were determined in complexes with indinavir, or the p2/NC substrate analog at resolutions of 1.10-1.50 Angstrom [2].
Target:	HIV Protease
References:	[1]. Stein, D.S., et al., A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS, 1996. 10(5): p. 485-92. [2]. Liu, F., et al., Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol, 2005. 354(4): p. 789-800.